Beeline Medicines reported positive topline data meeting primary SRI-4 endpoint at week 48 across all 3 doses in systemic lupus erythematosus.
|Slideshows|April 26, 2018
Serious Infection in Systemic Lupus Erythematosus
Updates from the 2018 European Lupus Society Meeting focus on the risk infection poses to patients with SLE.
Advertisement
References1. Simard J, Rossides M, Arkema E. Serious infection rates in systemic lupus erythematosus: a Swedish population-based assessment. Presented at: 11th SLEuro European Lupus Society Meeting; March 21-24, 2018; Dusseldorf, Germany.2. Iglesias AL, Pego-Reigosa JM, López-Longo FJ, et al. Bacteremia in systemic lupus erythematosus patients from Relesser Registry: risk factors, clinical and microbiological characteristics and outcomes. Presented at: 11th SLEuro European Lupus Society Meeting; March 21-24, 2018; Dusseldorf, Germany.
Advertisement
Related to this article
Marta Mosca, MD, PhD, highlighted a 43.0% DORIS rate and a 74.1% LLDAS rate during the 12-month follow-up period with anifrolumab.
A post-hoc of 5 phase 3 trials saw non-glucocorticoid DORIS remission and LLDAS attainment nearly doubled vs placebo at week 52.
Richard Furie, MD, discusses phase 2 JASMINE data showing sustained SRI-4 and LLDAS responses through 52 weeks.
Population data from Greater Manchester show Black, Asian, and mixed-ethnicity patients with lupus receive greater oral corticosteroid doses.
We're anticipating FDA decisions for tildrakizumab, obinutuzumab, and more, including a potential first targeted therapy for Sjögren's disease.
We reviewed new psoriatic arthritis approvals as well as data readouts from head-to-head trials and milestone data in IgG4-related disease.
Oral TLR7/8 inhibitor enpatoran earns FDA Breakthrough status for lupus skin disease, with Phase 2 CLASI-A gains and Phase 3 underway.
Advertisement
Advertisement